

Purpose

Contribute to the enrichment of quality of life around the world



Purpose
Contribute to the enrichment of quality of life around the world

Mission
Create innovative pharmaceuticals addressing diverse medical needs

2030 Vision
Innovative Global Healthcare Company Contributing to the Sustainable Development of Society

Core Value

Innovation
The introduction of new ideas, methods, or inventions

Integrity
The quality of being honest and of always having high moral principles

Accountability
Being responsible for the effects of your actions and being willing to explain or be criticized for them

Core Behavior

Be Inclusive & Embrace Diversity
Collaborate & Trust
Develop & Grow

One DS Culture

Aggregate of Purpose, Mission, Vision, Core Value, and Core Behavior

A History as a Partner to Patients for over 100 years

The Daiichi Sankyo Group leverages its century-long strengths in Science & Technology (S&T) forged by its predecessors to continue to take on the challenge of creating advanced pharmaceutical products.

Harnessing S&T as the driving force, we will continue to create innovative pharmaceuticals and realizing Healthcare as a Service (Haas)* by developing both a total care ecosystem and a total care platform through collaboration with other companies as we work toward our 2030 Vision and thereby “contribute to the enrichment of quality of life around the world.”

* Haas refers to providing health and medical services that are optimized and tailored to each individual by utilizing a variety of data and advanced technologies.

Steps of our 5-year business plan



History as a pharma innovator (major products over the years)

- 1899** Launched **Taka-Diastase**, a digestive enzyme agent
- 1902** Adrenalin, an adrenal cortex hormone agent
- 1910** Dr. Umetaro Suzuki, a future Sankyo scientific adviser, established a foundation for the theory of vitamins
- 1915** Began domestic manufacturing of Salvarsan, a therapeutic drug for syphilis
- 1922** Began manufacturing of **Bosmin**, a vasoconstriction/ hemostasis and asthma medicine
- 1951** Manufactured **Chloramycetin**, the first antibiotic produced in Japan
- 1965** Launched **Transamin**, a hemostatic and anti-inflammatory agent
- 1985** **Tarivid**, a broad-spectrum oral antimicrobial agent
- 1986** **Loxonin**, an anti-inflammatory analgesic
- 1989** **Mevalotin**, hypercholesterolemia treatment
- 1993** **Cravif**, a broad-spectrum oral antimicrobial agent
- 2002** Olmesartan (**Olmetec** in Japan and Europe, **Benicar** in the United States), an antihypertensive agent

2009 Efient , an antiplatelet agent	2010 Inavir , anti-influenza treatment	2011 Lixiana , an anticoagulant	2016	2019 Tarlige , pain treatment	2020 Enhertu , an anti-cancer agent (HER2 directed antibody drug conjugate)

Transition of unmet medical needs throughout time




2030 Vision
Innovative Global Healthcare Company
Contributing to the Sustainable Development of Society



A society that has realized Haas


Source: Presentation document of Society 5.0 “A New Society Pioneered by Science and Technology Innovation” by the Cabinet Office




Creating innovative pharmaceuticals by leveraging our strengths in Science & Technology (S&T)

Realizing Healthcare as a Service through development of both a total care ecosystem and a total care platform

Becoming an Innovative Global Healthcare Company with Strengths in



Number of employees by region




As of the end of March 2023



Financial Highlight (FY2022 results)




* Dividend on Equity = Total dividend amount / Equity attributable to owners of the Company



Non-Financial Highlight (FY2022 results)

Contribution to patients




Social



*Percentage of positive engagement survey responses in relation to our corporate culture and work environment

Environment



* Scope1+Scope2